Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blockbuster Patent Expiries Sparking Korean Generic War

This article was originally published in PharmAsia News

Executive Summary

With patents for a series of global blockbuster drugs expiring this year, South Korean pharma firms are fiercely competing to grab bigger pieces of the domestic generic market. Amid an ongoing patent invalidation suit concerning BMS’s Baraclude, Dong-A ST has been banned from producing and selling its generic version until the patent expires, while the Korean pharma association has warned its members against illegal rebates amid intensifying generic competition.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC088491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel